News Release, KYORIN Co,.Ltd.

RELEASE OF "MUCODYNE® DS50%"

Tue, 08 Jun 2010 14:02:12 +0900

KYORIN Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Keiji Hirai), a subsidiary of KYORIN Co., Ltd. announces the release of Mucodyne® DS50% (Nonproprietary name: L-Carbocisteine), a mucoregulating drug (for adults and children) today.

Change of Business Name

Wed, 26 May 2010 20:08:30 +0900

KYORIN Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Masahiro Yamashita) announces that a meeting of its Board of Directors held on May 11 resolved to propose a change of its business name at the ordinary general shareholders meeting scheduled for June 24, 2010. The change is subject to approval of the Articles of Incorporation at the shareholders meeting. Details are as follows:

New Medium-Term Business Plan Developed: "HOPE 100 Stage 1"

Wed, 26 May 2010 20:05:52 +0900

KYORIN Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Masahiro Yamashita) announces that it has developed a new medium-term business plan for the KYORIN Group. The plan is called "HOPE 100 Stage 1" and covers the period from FY2010 to FY2015. Under the new plan, the KYORIN Group will strive to realize its corporate philosophy of cherishing life and benefiting society by contributing to better health.

Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2010

Wed, 03 Feb 2010 10:55:04 +0900

MARKETING APPROVAL FOR "MUCODYNE® DS50%"

Mon, 18 Jan 2010 17:10:31 +0900

KYORIN Pharmaceutical Co., Ltd. (Headquarter: Tokyo, President: Keiji Hirai), a subsidiary of KYORIN Co., Ltd. announced today that the Ministry of Health, Labour and Welfare approved "MUCODYNE® DS50%" (INN: L-Carbocisteine), Mucoregulating drug, on January 15, 2010.

Application filed for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder

Thu, 07 Jan 2010 15:56:55 +0900

Kyorin Pharmaceutical Co., Ltd. ("Kyorin") (Tokyo, Japan, President: Keiji Hirai, Ph.D.), a wholly owned subsidiary of Kyorin Co., Ltd., and Ono Pharmaceutical Co., Ltd. ("Ono") (Osaka, Japan, President: Gyo Sagara) jointly announced that each company filed a new drug application for orally disintegrating tablet of imidafenacin (INN), a drug for the treatment of overactive bladder on December 24, 2009. It was originally launched in June 2007 as Uritos Tablets 0.1mg (by Kyorin) or Staybla Tablets 0.1mg (by Ono) in a form of conventional film coating tablets.

Execution of License Agreement on Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory

Thu, 05 Nov 2009 09:45:09 +0900

KYORIN Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Chiyoda-ku, Tokyo, President: Keiji Hirai, Ph.D.), a wholly owned subsidiary of KYORIN Co., Ltd., today entered into a License Agreement for Neramexane, a tinnitus treatment product currently being developed in the US and Europe, with Merz Pharmaceuticals GmbH ("Merz") (Head office: Frankfurt am Main, Germany, CEO: Martin Zügel, Ph.D.) for the territory of Japan.

KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries

Tue, 29 Sep 2009 14:10:05 +0900

First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2010

Wed, 05 Aug 2009 15:55:26 +0900

Grant of Marketing Right to Senju Pharmaceutical on Gatifloxacin Ophthalmic Solution in China

Mon, 27 Jul 2009 15:31:42 +0900

KYORIN Co., Ltd. announces that its wholly owned subsidiary of KYORIN Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Tokyo, President: Keiji Hirai, Ph.D.) today signed a License Agreement with Senju Pharmaceutical Co., Ltd. ("Senju") (Head office: Osaka, President: Yukoh Yoshida), concerning the grant of an exclusive marketing right to Senju on Gatifloxacin ophthalmic solution for China. Gatifloxacin is a broad spectrum synthetic antibacterial agent originated by Kyorin.

Change of Representative Director and President at KYORIN Pharmaceutical

Fri, 03 Apr 2009 19:25:09 +0900

KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Co., Ltd., announces that a meeting of its Board of Directors held on April 3, 2009 informally resolved to make the change of KYORIN Pharmaceutical's Representative Director and President.
The change will be made pending a resolution of the ordinary general shareholders meeting of KYORIN Pharmaceutical scheduled in June 2009 and a subsequent meeting of the Board of Directors of KYORIN Pharmaceutical.

Change of Representative Director and President at KYORIN

Fri, 03 Apr 2009 19:18:22 +0900

KYORIN Co., Ltd. announces that a meeting of its Board of Directors held on April 3, 2009 informally resolved to make the change of the Company's Representative Director and President.
The change will be made pending a resolution of the ordinary general shareholders meeting of the Company scheduled in June 2009 and a subsequent meeting of the Board of Directors.

KYORIN Announces Dissolution of Subsidiary

Thu, 19 Mar 2009 11:26:21 +0900

KYORIN Co., Ltd. announced today that a meeting of the Board of Directors held on March 19, 2009 resolved to dissolve BISTNER Co., Ltd., a consolidated subsidiary of the Company.

KYORIN Subsidiary (Investment LPS) to Be Dissolved

Thu, 19 Mar 2009 11:24:18 +0900

KYORIN Co., Ltd. announces that a meeting of the Board of Directors held on March 19, 2009 resolved to dissolve BISTNER First Investment LPS, the Company's consolidated subsidiary.

Execution of Licensing and Supply Agreement on Uritos® Tablets with SPIMACO

Fri, 27 Feb 2009 15:19:28 +0900

KYORIN Co., Ltd. announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd. (Head office: Tokyo, President: Itaru Kojo) has entered into a License and Supply Agreement with Saudi Pharmaceutical Industries & Medical Appliances Corporation ("SPIMACO") (Head office: Riyadh, Saudi Arabia, President: Dr. Abdullah Bin Abdulaziz Al Abdulkader), under which KYORIN Pharmaceutical granted to SPIMACO an exclusive right to develop, register, import, and market Uritos® Tablets (generic name: Imidafenacin), a therapeutic agent for overactive bladder (OAB) in thirteen countries in the Middle East and North Africa (MENA) region, including Saudi Arabia.